AI-guided treatment for HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether an artificial intelligence model can help doctors choose the best targeted therapy before surgery for HER2-positive breast cancer (a type of breast cancer with a protein called HER2). The goal is to improve how well the treatment works and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18–75 years old
- You have stage II–III HER2-positive breast cancer that hasn't spread to other parts of your body
- Your cancer is confirmed by lab tests showing HER2 positivity (IHC 3+ or IHC 2+ with positive ISH)
- You have not received any prior chemotherapy, targeted therapy, or other cancer treatments
- Your heart function, kidney function, and blood counts are healthy enough for treatment
- You are willing to use effective birth control during the trial and for 3 months after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses artificial intelligence to analyze tissue samples and predict how well a targeted therapy called Pyrotinib works for advanced breast cancer. It aims to help doctors choose the best treatment for each patient.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests a new antibody-drug conjugate, SHR-A1811, against the combination of pyrotinib and capecitabine in people with HER2-positive advanced breast cancer that no longer responds to trastuzumab (Herceptin). Researchers want to see if SHR-A1811 works better than the standard treatment.
This trial tests a new drug called SHR-A1811, given either alone or with the hormone therapy letrozole, before surgery for women with early-stage breast cancer that is hormone receptor positive and HER2-low. The goal is to see if this treatment can shrink the tumor before surgery.
This trial tests a new drug, SHR-1811, combined with carboplatin for advanced breast cancer that has HER2 expression (including low levels). It is for people who have already tried standard treatments and their cancer has spread or cannot be removed by surgery.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.